170570-75-9 : Celecoxib Bromo Impurity

It is a selective cyclooxygenase-2 inhibitor, By inhibiting prostaglandin synthesis non-steroidal anti-inflammatory drugs cause mucosal damage and ulceration. Celecoxib poses less of an ulceration risk than other NSAIDS, owing to its decreased effect on gastric mucosal prostaglandin synthesis when compared to placebo, also exerts anticancer effects by binding to the cadherin-11 protein, which is involved in the progression of tumors and inhibiting the 3 phosphoinositide-dependent kinase-1 signaling mechanism, which is used to treat osteoarthritis, rheumatoid arthritis, and to reduce polyps in familial adenomatous polyposis.

Additional information on CAS 170570-75-9

Catalogue No.

VE007713

CAS No.

170570-75-9

Molecular Formula

C17H13BrF3N3O2S

Molecular Weight

460.27 g/mol

Parent drug

Celecoxib

IUPAC Name

4-(5-(4-(Bromomethyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

Synonyms

N/A

References

Xu, C., Gu, K., Yasen, Y., & Hou, Y. (2016). Efficacy and Safety of Celecoxib Therapy in Osteoarthritis. Medicine, 95(20), e3585. https://doi.org/10.1097/md.0000000000003585

Status

In-stock

[rfq_list]

Login first to add product to RFQ List

Request a quote

170570-75-9 : Celecoxib Bromo Impurity

170570-75-9 : Celecoxib Bromo Impurity
Catalogue No.

VE007713

CAS No.

170570-75-9

Molecular Formula

C17H13BrF3N3O2S

Molecular Weight

460.27 g/mol

Parent drug

Celecoxib

IUPAC Name

4-(5-(4-(Bromomethyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

Synonyms

N/A

References

Xu, C., Gu, K., Yasen, Y., & Hou, Y. (2016). Efficacy and Safety of Celecoxib Therapy in Osteoarthritis. Medicine, 95(20), e3585. https://doi.org/10.1097/md.0000000000003585

Status

In-stock

ListName

Celecoxib Bromo Impurity

Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url
 
Hidden